Review date: June 2006; expiry date: December 2006.
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias
Article first published online: 14 FEB 2003
British Journal of Haematology
Volume 120, Issue 4, pages 556–573, February 2003
How to Cite
Allford, S. L., Hunt, B. J., Rose, P., Machin, S. J. and on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology (2003), Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. British Journal of Haematology, 120: 556–573. doi: 10.1046/j.1365-2141.2003.04049.x
- Issue published online: 14 FEB 2003
- Article first published online: 14 FEB 2003
- microangiopathic haemolytic anaemia;
- thrombotic thrombocytopenic purpura;
- haemolytic uraemic syndrome;
- gestational thrombotic miroangiopathic anaemia;
- management guidelines
Thrombotic thrombocytopenic purpura (TTP) was first described by Moschowitz (1924). The classic pentad of diagnostic features has been recognized for many years. However, several other syndromes are also characterized by similar features. These include haemolytic uraemic syndrome (HUS), eclampsia and the HELLP syndrome (haemolysis, elevated liver enzymes, low platelets). The concept has arisen that they might represent an overlapping spectrum of disease, although with varying pathophysiological features (see Table I). The recent characterization of a novel von Willebrand factor (VWF)-cleaving metalloprotease activity (Furlan et al, 1996; Tsai, 1996) and its deficiency or inhibition in some forms of microangiopathic haemolysis (Furlan et al, 1997, 1998; Tsai & Lian, 1998) has led to speculation that a pathogenic mechanism for individual patients can be defined more readily and appropriate treatment introduced more rapidly. However, there is still considerable confusion, a lack of properly conducted randomized clinical trials and poor co-ordination of clinical data. This is, in part, because these patients present to a range of specialists including haematologists, obstetricians, nephrologists and infectious disease physicians. These guidelines attempt to define the various clinical subtypes, specify the recognized diagnostic features and look critically at management options. It is acknowledged that there is a lack of evidence from well-conducted studies on which to support some of the recommendations made.
Thrombotic thrombocytopenic purpura
Diagnosis and clinical features
TTP is a clinical diagnosis. It is characterized by the classic pentad of thrombocytopenia, microangiopathic haemolytic anaemia, fluctuating neurological signs, renal impairment and fever, often with insidious onset. Neurological impairment has multiple manifestations including headache, bizarre behaviour, transient sensorimotor deficits (TIAs), seizure and coma. Presence of coma at presentation is a poor prognostic indicator (Pereira et al, 1995; Sarode et al, 1997). Additional complications may be seen: gastrointestinal ischaemia (manifest as abdominal pain) and serous retinal detachment are recognized associations. However, up to 35% of TTP patients do not have neurological symptoms or signs at presentation (Rock et al, 1991). As the triad of acute renal insufficiency, MAHA and thrombocytopenia defines HUS, diagnostic uncertainty may arise. Moreover, fever and renal impairment are present in only a minority of patients (Rock et al, 1991, 1998). In practice, therefore, a diagnosis of TTP may be made in the presence of a microangiopathic haemolytic anaemia and thrombocytopenia in the absence of any other identifiable cause.
A number of different clinical variants of TTP have been documented. Clinical subtype may influence management and those recognized are listed in Table II.
|Acute idiopathic TTP||No identifiable precipitant|
|No subsequent relapse|
|Secondary TTP||Drugs||oral contraceptive pill|
|Post bone marrow transplantation|
|Systemic lupus erythematosus|
|E. coli 0157:H7|
|Intermittent TTP||Recurrent episodes at unpredictable intervals|
The predominant histological abnormality found in TTP is the formation of platelet microvascular thrombi. The renal and cerebral circulations are primarily affected, thus accounting for the clinical features of the disease. Excessive platelet aggregation occurs when platelet-rich plasma (PRP) from patients with congenital TTP is exposed to shear stress (Moake et al, 1994). This is mediated by ultra-large VWF multimers (ULVWF) (Moake et al, 1994; Karpman et al, 1997). ULVWF are not a normal constituent of circulating plasma. Instead, VWF circulates as smaller multimeric forms resulting from proteolytic degradation of ULVWF. VWF fragments with mobility corresponding to 189, 176 and 140 kDa are consistently detected in normal plasma in addition to the predominant 225 kDa subunit (Zimmerman et al, 1986; Tsai et al, 1991). These originate as a consequence of cleavage of a single peptide bond between residues Tyr-842 and Met-843 of the mature subunit (Dent et al, 1991). Identical fragments may be generated in vivo by a novel metalloproteinase activity (Furlan et al, 1996; Tsai, 1996). The protease has recently been characterized as a new member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin type-I motif) family, ADAMTS13 (Fujikawa et al, 2001; Gerritsen et al, 2001; Levy et al, 2001). Deficiency of this VWF-cleaving protease (VWF-CP) activity has been associated with acquired and congenital TTP. While all cases of idiopathic TTP have, to date, been associated with severe protease deficiency, secondary TTP may occur in the context of normal protease activity (Veyradier et al, 2001). In a series of 111 patients with thrombotic microangiopathies of whom 66 manifested with TTP (25 idiopathic and 41 secondary) and 45 with HUS, protease deficiency had a sensitivity of 89% and specificity of 91% for TTP. Initial reports suggested that idiopathic TTP is secondary to an inhibitory auto-antibody of IgG subtype (Furlan et al, 1998; Tsai & Lian, 1998), but in the above series, a protease inhibitor was identified in only 14 patients (56%). While congenital TTP appears secondary to a constitutional deficiency (Furlan et al, 1997, 1998), presentation may be delayed until adulthood (Lämmle et al, 2001). Cirrhosis (Mannucci et al, 2001), uraemia (Mannucci et al, 2001), acute inflammation (Mannucci et al, 2001), disseminated intravascular coagulation (DIC) (Loof et al, 2001) and malignancy (Oleksowicz et al, 1999) have now also been associated with reduced VWF-CP activity. Thus, although sensitive, reduced VWF-CP activity is not specific for TTP. Moreover, this model fails to explain the anatomical distribution of thrombi. The endothelium is a heterogeneous organ and is subject to regulation by multiple factors, including cytokines (Drake et al, 1993), microenvironment (Aird et al, 1997) and shear stress (White & Fujiwara, 1986). Alterations in any one of these parameters could influence either VWF-CP activity per se or the susceptibility of VWF to proteolysis.
Laboratory features and investigation
TTP is often characterized by severe thrombocytopenia, which may be useful in its differentiation from HUS. However, in one series, although the mean platelet count was lower in TTP than HUS (18 × 109/l vs 36 × 109/l), there was a wide range and considerable overlap (Vesely et al, 2000). Severe thrombocytopenia at diagnosis (platelet count < 20 × 109/l) has been suggested to be a poor prognostic indicator, conferring increased mortality (Rock et al, 1998), although this is not a uniform observation (Sarode et al, 1997). Thrombocytopenia is typically accompanied by overt microangiopathic haemolysis. Thus, examination of the blood film usually shows striking red cell fragmentation and polychromasia. However, schistocytes may be absent from the peripheral blood film in the first 24–48 h following clinical presentation. Routine coagulation profiles are usually normal (Monteagudo et al, 1991; Sagripanti et al, 1996; Rock et al, 1998), although slight increases in D-dimer, fibrin degradation products and thrombin–anti-thrombin complex (TAT) may be seen (Monteagudo et al, 1991; Sagripanti et al, 1996; Wada et al, 1998). Secondary DIC may, however, arise from prolonged tissue ischaemia and is an ominous prognostic indicator. Evidence of endothelial perturbation is demonstrated by increased plasma levels of plasminogen activator inhibitor (PAI-1) (Anthony et al, 1998) and thrombomodulin. The latter has also been identified as a poor prognostic factor (Wada et al, 1998). Plasma VWF levels are often elevated acutely (Rock et al, 1998). Abnormalities of VWF multimers are also common and were identified in 86% of patients either at the onset of or during an acute episode of TTP (Moake & McPherson, 1989). These ranged from the presence of ULVWF multimers in 31% to a relative decrease in the largest plasma VWF forms in 36%. Acute changes in VWF multimeric distribution do not appear to correlate with clinical outcome. However, the finding of ULVWF multimers during periods of remission has been associated with intermittent TTP (Moake & McPherson, 1989). Renal function is normal in the majority of patients: only 18% patients presenting to the Canadian Apheresis Group had evidence of renal impairment (Shumak et al, 1995). Liver function tests often show not only hyperbilirubinaemia but also a raised transaminase level. This is thought to represent hepatic ischaemia. Evans' syndrome may be excluded by a negative direct anti-globulin test. Recommended diagnostic laboratory investigations to be performed at presentation are given in Table III.
|Full blood count and blood film|
|Clotting screen including fibrinogen and D-dimers|
|Urea and electrolytes|
|Liver function tests|
|Direct antiglobulin test|
In those TTP patients in whom significant renal impairment is a feature, it may be impossible to confidently exclude HUS. Where there is doubt, a presumptive diagnosis of TTP should be made and plasmapheresis initiated. Occasionally renal biopsy performed after recovery of the platelet count may allow accurate retrospective diagnosis. In TTP, arteriolar and capillary thrombosis is prominent. Thrombi are largely composed of platelets and stain strongly for VWF. Only weak staining for fibrin and fibrinogen is seen in contrast to those thrombi formed in DIC (Asada et al, 1985). Aneurysmal dilatation of arterioles may lead to the formation of glomeruloid structures with relative sparing of the glomeruli (Katoh & Shigematsu, 1999). These features should be contrasted with those seen in HUS when the primary histological changes are glomerular and arteriolar fibrin thrombi and subendothelial widening of the glomerular capillary wall on electron microscopy (Remuzzi & Ruggenenti, 1995).
If a diagnosis of TTP is made, consideration must be given to the presence of precipitants. These are drugs, autoimmune disease, malignancy and infection, particularly Escherichia coli 0157:H7 and human immunodeficiency virus (HIV). Although E. coli 0157:H7 is more closely linked with HUS, there have been cases with typical TTP features (Morrison et al, 1986; Kovacs et al, 1990). Of note VWF-CP deficiency was detected in one of 29 children with epidemic HUS, 25 of whom were positive for verotoxin (Hunt et al, 2001). In some series, up to 14% of TTP episodes have been associated with HIV infection (Ucar et al, 1994), although mortality data from the United States for 1988–1991 gives a figure of only 4·4% (Torok et al, 1995). Risk appears greatest at CD4 counts of less than 250 × 109/l (de Man et al, 1997). Serological testing for HIV should, therefore, be performed at diagnosis in all patients. As treatment (see below) results in multiple donor exposure, hepatitis B and C serology is also recommended in all patients at presentation.
Recommendation. While there is no available diagnostic test for TTP, TTP may be diagnosed and treatment initiated if a patient presents with a microangiopathic haemolytic anaemia and thrombocytopenia in the absence of any other identifiable clinical cause. Routine investigations at presentation should include the following: full blood count, film, clotting screen, lactate dehydrogenase (LDH), direct anti-globulin test, urea and electrolytes, liver function tests, and urine dipstick for protein. An underlying precipitant should be considered. It is recommended that HIV and hepatitis serology tests are performed at diagnosis (Grade C, level IV).
The mainstay of treatment of acute TTP is daily plasma exchange. Prior to its institution, mortality rates were in excess of 90% and have now fallen to 10–30%. Plasma exchange is superior to plasma infusion. A prospective randomized study performed by the Canadian Apheresis Group assigned a total of 102 patients to receive either plasma exchange or infusion with fresh-frozen plasma (FFP) on 7 of the first 9 d after entry to the trial. Plasma exchange resulted in significantly superior response rates at both the end of the first treatment cycle and at 6 months (response rates 47% and 78%vs 25% and 49% respectively). Mortality was also reduced at 22%vs 37% (Rock et al, 1991). Plasma exchange should be instituted within 24 h of presentation as delay in treatment initiation may increase treatment failure (Pereira et al, 1995). Moreover, it would seem appropriate to commence plasma exchange as soon as practicable if renal impairment, cardiac failure or coma is present. Reduced level of consciousness has been identified as a poor prognostic factor with an overall survival of 54% (Sarode et al, 1997). The duration of plasma exchange therapy required to achieve remission is highly variable. The average number of procedures required for remission in the above study was 15·8 (range 3–36). As the premature omission of a single plasma exchange may be associated with exacerbation, patients should be treated in centres able to provide a daily plasmapheresis service.
Although undoubtedly efficacious, the optimal plasma exchange regimen has not been determined. In the Canadian apheresis trial, 1·5 × plasma volume exchange was performed on the first 3 d followed by 1·0 plasma volume exchange thereafter. Whether this intensity is superior to single plasma volume replacement from presentation is unclear. Currently, many centres initiate single-volume plasma exchange at presentation, reserving more intensive exchange for resistant cases. Similarly, the optimal duration of plasma exchange is unknown. It is empirically recommended that daily exchanges should continue for a minimum of 2 d after complete remission is obtained, defined as normal neurological status, platelet count and LDH with a rising haemoglobin. This is in agreement with the American Association of Blood Banks (AABB), which recommends daily plasma exchange until the platelet count is above 150 × 109/l for 2 to 3 d (AABB Extracorporeal Therapy Committee, 1992). Although it is accepted practice to taper the frequency of exchange procedures rather than stopping abruptly in an effort to minimize the risk of early relapse; this is not based on randomized clinical trials.
The optimal replacement fluid administered also remains contentious. Possibly of note, cryosupernatant lacks the largest VWF multimers that are present in FFP and cryoprecipitate. Cryosupernatant is at least as efficacious as FFP. When used in previously untreated patients, the response rate was 75% after seven exchanges. Survival was 95% at 1 month, which compared favourably with historical control subjects treated with FFP (Rock et al, 1996). In contrast, a prospective randomized trial performed by the North American TTP Group failed to identify a significant difference in outcome between plasmapheresis with FFP or cryosupernatant from diagnosis. It should be noted, however, that only 27 patients were included in this trial (Zeigler et al, 2001). Larger trials are required to address this issue and a randomized controlled trial comparing plasma exchange with FFP versus cryosupernatant is currently being performed in Canada.
Side-effects secondary to plasmapheresis are common. In one study, 9·7% of procedures were complicated by adverse reactions with anaphylactoid reactions occurring in 0·25% (Mokrzycki & Kaplan, 1994). Solvent/detergent-treated (S/D) plasma not only reduces viral risk but may be beneficial in reducing allergic reactions. This is because the process of plasma pooling results in extreme dilution of those antibodies responsible for immune-mediated reactions. S/D plasma has a similar favourable multimer profile to cryosupernatant and has been used as replacement fluid from presentation (Evans et al, 1999). However, numbers treated are small and there is no published comparative data with FFP or cryosupernatant. Further clinical experience is required to ascertain the role of S/D plasma in the primary treatment of TTP.
Although plasma exchange remains the treatment of choice, plasma infusion (30 ml/kg/d) may still be indicated if there is to be an unavoidable delay in plasma exchange. It must be undertaken with care, however, as cardiac function may be compromised and cardiac failure can be precipitated.
Recommendation. Single-volume daily plasma exchange should be commenced at presentation (Grade A, level Ib) and ideally within 24 h of presentation (Grade C, level IV). Plasma exchange using cryosupernatant may be more efficacious than that using FFP (Grade B, level III). Daily plasma exchange should continue for a minimum of 2 d after complete remission is obtained (Grade C, level IV).
Corticosteroids. Steroids have been widely used in the treatment of TTP although there is scanty evidence documenting their efficacy. However, patients with TTP lacking central nervous system abnormalities other than headache have been shown to respond to steroid treatment alone, although of 54 such patients 44% required plasma exchange because of deterioration or failure to improve (Bell et al, 1991). Steroids have also been combined with plasma exchange in initial treatment of TTP. The addition of intravenous methylprednisolone 2 mg/kg/d to daily plasma exchange resulted in a complete remission rate of 76% (Perotti et al, 1996). As yet, no trial has addressed whether such a combination approach is superior to plasma exchange alone. Not surprisingly, there is no consensus regarding dose or mode of administration. Despite the lack of evidence, the addition of steroids to plasma exchange as standard therapy is attractive. Recent findings suggest that a functional deficiency of a novel VWF-CP activity secondary to a circulating inhibitory antibody of IgG subtype is of prime importance in the pathogenesis of TTP (Furlan et al, 1998; Tsai & Lian, 1998). It would, therefore, appear reasonable to institute steroids in all patients.
Recommendation. All patients should receive adjuvant corticosteroid therapy (Grade B, level III). To achieve potent immunosuppression while minimizing long-term steroid side-effects, pulse methylprednisolone 1 g i.v. for 3 d is recommended (Grade C, level IV).
Anti-platelet agents. The use of anti-platelet agents in TTP remains controversial. Ticlopidine and its analogue clopidogrel inhibit ADP–platelet interactions and interfere with shear-induced aggregation and might, therefore, be predicted to be of use in TTP. Certainly ticlopidine appeared to reduce the risk of subsequent relapse from 21·4% to 6·25% when used as maintenance therapy for 12 months after remission of TTP was achieved (Bobbio-Pallavicini et al, 1997). However, at publication, follow-up in this trial was incomplete. Subsequently ticlopidine (Bennet et al, 1998) and clopidogrel (Bennet et al, 2000) have been associated with TTP. The estimated incidence of ticlopidine-associated TTP is 1 per 1600–5000 patients treated while that following clopidogrel is 1·5–5·8 per million treated. As the latter is similar to the reported incidence of idiopathic TTP an association remains controversial. Nevertheless in both cases, antibody inhibitors to VWF-CP have been identified (Bennet et al, 2000; Tsai et al, 2000). In keeping with this, plasmapheresis is effective treatment with reported survival rates of 76–91% and is superior to plasma infusion (Bennet et al, 1998, 2000). For these reasons, ticlopidine and clopidogrel should be avoided in patients with a previous history of TTP.
Aspirin and dipyridamole have both been used in the initial treatment of TTP. A 78% response rate at 6 months was achieved when aspirin and dipyridamole were administered in conjunction with plasma exchange (Rock et al, 1991). In a prospective randomized trial designed to address the effect of the addition of aspirin and dipyridamole to standard treatment (plasma exchange and steroids), a similar overall response was obtained in both groups. There was, however, a trend to reduced mortality at 15 d in those treated with anti-platelet agents. No excess haemorrhage was seen in the treatment group (Bobbio-Pallavicini et al, 1997), in contrast to the findings of a small retrospective study in which serious bleeding complications occurred in five of 14 patients receiving anti-platelet medication (Rosove et al, 1982). It should be noted, however, that large doses were administered in these last patients (0·9–2·7 g/d aspirin). Although not yet of proven benefit, there is nevertheless a rationale for instituting aspirin therapy when the platelet count rises over 50 × 109/l as anecdotally a rapid rise in platelet count during recovery has been associated with thromboembolic events.
Recommendation. Low-dose aspirin (75 mg o.d.) should be commenced on platelet recovery (platelet count > 50 × 109/l) (Grade C, level IV).
Supportive therapy. Red cell transfusion is an essential component of treatment. However, there is no single reliable parameter to guide the need for red cell transfusion. Identical survival rates resulted when a transfusion was given based on a haemoglobin threshold of 7 g/dl rather than 10 g/dl in euvolaemic critically ill patients (Hebert et al, 1999). As TTP may be complicated by rapid haemolysis and cardiac insufficiency secondary to myocardial microvascular thrombi, a patient should be transfused according to critical clinical evaluation after due consideration of the risks and benefits of transfusion. All patients should receive folic acid supplementation. Platelet transfusions are contraindicated unless there is life-threatening haemorrhage as they have been temporally associated with disease exacerbation (Harkness et al, 1981; Gordon et al, 1987). Some centres advocate the use of prophylactic phenytoin in an attempt to minimize secondary seizures. However, neurological features are completely absent in 35% of patients and seizures only occur in a minority of the remaining patients (Rock et al, 1991). Secondary rather than primary prophylaxis of seizures with phenytoin would, therefore, seem appropriate. Although fever is one of the defining features of TTP, an underlying infection should be sought actively; if untreated, occult infection may prevent response to plasma exchange or precipitate early relapse. Hepatitis B vaccination should be given to all patients and can be safely administered using a platelet threshold of 50 × 109/l.
Recommendation. Red cell transfusion should be administered according to clinical need (Grade B, level III). Folate supplementation is required in all patients. Platelet transfusions are contraindicated in TTP unless there is life-threatening haemorrhage. Hepatitis B vaccination is recommended in all patients (Grade C, level IV).
Management of refractory disease
Despite the improvement in survival, there remains a subgroup with a slow or incomplete response to plasma exchange ± steroids. Refractory disease may be defined as persistent thrombocytopenia (platelet count < 150 × 109/l) or LDH elevation after a total of seven daily plasma exchange procedures. Treatment of this group of patients is difficult and a wide range of additional approaches has been used. Unfortunately randomized clinical trials have not been performed because of the rarity and heterogeneity of this condition.
Manipulation of plasma exchange. There are reports documenting responses to plasma exchange in refractory cases of TTP following the substitution of either cryosupernatant (Molinari et al, 1993) or S/D plasma (Harrison et al, 1996) for FFP. Like cryosupernatant, S/D plasma lacks the largest plasma VWF multimers and this may be of importance. If, therefore, there is a suboptimal response to plasma exchange after 7 d or rapid clinical deterioration despite daily plasma exchange, an alternative replacement fluid should be substituted. While methylene blue (MB)-treated fresh-frozen plasma has been used in the management of TTP (Martinez et al, 2000), clinical experience is extremely limited at present and, unlike S/D plasma, VWF multimeric structure is not modified. Whether MB cryosupernatant has a role in the management of TTP will require further clinical experience.
Intensification of plasma exchange has also been used in cases of refractory TTP with the introduction of either 12 h or double-volume plasma volume exchanges. At present, this approach is empirical.
Recommendation. In the presence of refractory disease an alternative plasma product lacking high-molecular-weight VWF multimeric forms, cryosupernatant or S/D plasma should be used for plasma exchange (Grade C, level IV). Intensification of plasma exchange procedures should also be considered in life-threatening cases (Grade C, level IV).
Vincristine. Although vincristine is often used in the treatment of refractory TTP, published literature supporting its efficacy comprises only case reports or small retrospective studies. Nevertheless, these suggest that the administration of vincristine in refractory TTP may be temporally associated with platelet recovery (Welborn et al, 1990; O'Connor et al, 1992; Bobbio-Pallavicini et al, 1994). A role for the early administration of vincristine (within 3 d of presentation) has also been advocated following a small retrospective study (Mazzei et al, 1998). However, such practice would carry a risk of inducing neuropathy without proof of clinical benefit. Until this finding can be corroborated by larger controlled trials, vincristine should be reserved for refractory cases. A number of dosage regimens have been employed with no clear advantage for any single one. A schedule of 1 mg repeated every 3 to 4 d for a total of four doses is popular as it may limit toxicity while retaining efficacy. Higher dose regimens have, however, been used apparently successfully. The mechanism of action of vincristine remains unclear.
Recommendation. Vincristine 1 mg repeated every 3 to 4 d for a total of four doses is recommended in refractory TTP (Grade C, level IV).
Cyclophosphamide. Cyclosphosphamide has also been advocated for the treatment of TTP, particularly those in patients who experience recurrent relapses (severe intermittent TTP) (Bird et al, 1990; Udvardy & Rak, 1990; Strutz et al, 1998). Both daily dosing and pulsed therapy have been used successfully, although reported numbers are extremely low. Cyclophosphamide is known to be a potent immunosuppressant and this is thought to underlie its efficacy.
Cyclosporine. Although cyclosporine is associated with an increased risk of post-bone marrow transplant microangiopathy, there are reports of its successful application to the treatment of refractory (Hand et al, 1998), severe intermittent (Pasquale et al, 1998) and post-autologous bone marrow transplantation (BMT) TTP (Van Ojik et al, 1997). This is consistent with the current autoimmune model of TTP and cyclosporine's immunosuppressive action. While spontaneous resolution cannot be excluded in these patients, clinical and haematological response uniformly occurred 7 to 14 d after initiating treatment. Cyclosporine may, therefore, prove to be a useful therapeutic modality in these difficult patients. However, much remains unanswered. The optimal duration of treatment is unknown, with relapses documented after cessation of therapy (Hand et al, 1998; Pasquale et al, 1998). The optimal target therapeutic range is also unknown: trough serum levels of 200–300 µg/l have been used. The potential toxicity of this drug must also be considered.
Recommendation. Intensive immunosuppression using either cyclophosphamide or cyclosporine is indicated in severe refractory or recurrent TTP (Grade C, level IV).
Treatment of malignancy-associated and post-bone marrow transplant-associated TTP
The advent of VWF-CP assays is now beginning to confirm the clinical suspicion that TTP currently represents a heterogeneous group of conditions. It has long been recognized that plasma exchange is rarely effective in the treatment of BMT-associated TTP, suggesting that an alternative pathological process might be involved. This theory is supported by the recent finding that VWF-CP activity was normal in seven and only moderately reduced in one of eight patients with BMT-associated TTP (van der Plas et al, 1999). Effective treatment for this group of patients is, however, lacking. Resolution of autologous BMT-associated TTP has been reported following initiation of cyclosporine (Van Ojik et al, 1997), although paradoxically cyclosporine therapy is a recognized risk factor, along with total body irradiation, for allogeneic BMT-associated TTP. In the latter setting, cyclosporine should be stopped. Whether protein-A column immunoabsorption might be useful in such patients is unclear. Certainly this technique has been successfully employed in the treatment of malignancy-associated TTP in which plasma exchange is often found to be ineffective. In one small retrospective series, it was found to be of benefit in seven of 10 patients who had been unresponsive to plasma exchange (Gaddis et al, 1997).
Recommendation. Malignancy and BMT-associated TTP are often refractory to plasma exchange. Protein-A column immunoabsorption may be considered (Grade C, level IV).
Management of relapse
Although remission is now attained in over 80% patients, subsequent relapse remains problematic. Data from the Canadian Apheresis Group estimate that over a 10-year follow-up period up to 36% of TTP patients relapse. Relapse has occurred up to 8 years after the index event (Shumak et al, 1995). All patients should be aware of the possibility of relapse and advised to report early if symptoms suggestive of relapse develop. At present, it is impossible to identify those patients at greatest risk, although the presence of ULVWF during periods of remission is associated with intermittent disease (Moake & McPherson, 1989). There is no consensus whether there is any effective intervention that might reduce this risk. Splenectomy has been advocated as a means of reducing the relapse rate. One small retrospective study including six patients showed encouraging results with relapse rates falling from 2·3 ± 2·0 to 0·1 ± 0·1 events per year when the operation was performed during haematological remission (Crowther et al, 1996). However, acute exacerbations of TTP have occurred post-operatively and this approach should not be undertaken lightly. Anti-platelet medication has also been proposed as a possible alternative. There was a trend to reduced relapse rate in those patients receiving ticlopidine for 12 months after attaining remission (Bobbio-Pallavicini et al, 1997). As ticlopidine has itself now been associated with TTP (Bennet et al, 1998), this is no longer advocated, although some centres empirically commence patients on aspirin 75 mg/d. There are no published data supporting such an approach.
Recommendation. Relapse is common. Urgent self-referral is advised if a patient develops symptoms suggestive of relapse. Splenectomy may reduce the risk of relapse (Grade B, level III).
Congenital TTP is extremely rare with fewer than 50 patients reported in the literature. It classically presents during infancy or early childhood with recurrent episodes of haemolysis and thrombocytopenia at predictable intervals (usually every 21–28 d) (Chintagumpala et al, 1992; Moake et al, 1994). In contrast, milder variants have been described in which patients may present at a later age with intermittent episodes of TTP (Karpman et al, 1996; Barbot et al, 2000). Such episodes are characterized by the classic clinical pentad of microangiopathic haemolytic anaemia, thrombocytopenia, fluctuating neurological signs, renal dysfunction and fever, and often appear to be precipitated by febrile illnesses (Upshaw, 1978; Karpman et al, 1996). Both presentations are typified by the presence of circulating ULVWF multimers during remission periods consistent with defective post-secretory VWF processing (Moake & McPherson, 1989; Chintagumpala et al, 1992). Indeed, congenital TTP has recently been associated with an absolute deficiency of a novel VWF-CP (less than 5% normal activity) (Furlan et al, 1997, 1998; Allford et al, 2000). This protease has recently been identified as ADAMTS13, and DNA analysis has identified mutations within the ADAMTS13 gene located on chromosome 9q34 in those congenital TTP pedigrees studied (Levy et al, 2001). This is consistent with the recognized clinical finding that plasma infusion is effective treatment for this condition and an exchange procedure is not required.
Successful long-term maintenance can be achieved in severe congenital TTP through prophylactic infusion with FFP (Moake et al, 1985; Barbot et al, 2000), cryosupernatant (Moake et al, 1985) or S/D plasma (Moake et al, 1994). Treatment is usually required every 3 to 4 weeks (Chintagumpala et al, 1992). Plasma infusion may, however, be reserved for symptomatic episodes in milder cases (Karpman et al, 1996; Allford et al, 2000). Viral inactivation and the consequent lower risk of transfusion-transmitted infection obviously makes S/D plasma an attractive treatment option. It should be remembered, however, that non-lipid viruses are not inactivated by this procedure and that the product is derived from large donor pools. Hepatitis vaccination should be offered to all patients.
Recommendation. Prophylactic plasma infusions should be administered every 3 to 4 weeks in severe congenital TTP (Grade B, level IIb). Plasma infusion may be reserved for symptomatic episodes in milder variants (Grade C, level IV). A virally inactivated product should be given if available (Grade C, level IV). Hepatitis B vaccination is recommended for all patients (Grade B, level III).
Haemolytic uraemic syndrome
The haemolytic uraemic syndrome is characterized by a microangiopathic haemolytic anaemia, thrombocytopenia and renal failure (Gasser et al, 1955). The disease may also be associated with more extensive multiorgan disease, including enterocolitis, neurological complications, liver dysfunction, pancreatic and cardiac problems. In such patients, particularly when neurological problems are present, there is clinical overlap with TTP (Seigler, 1994) (see Table I). Where possible, it is important to distinguish between the two conditions in order to plan the most appropriate clinical management.
Clinical features and pathogenesis
The epidemic form (D+) is associated with a prodromal illness often with bloody diarrhoea in contrast to the rare sporadic or atypical cases (D–) (Milford et al, 1990). HUS is seen increasingly following outbreaks of infection with verotoxin (VT)-producing organisms (Table IV). It represents a growing public health problem (Dundas & Todd, 1999). E. coli 0157:H7 is the most commonly notified VT-producing organism in the United Kingdom. Clinical manifestations may vary from an asymptomatic infection through to bloody diarrhoea, haemorrhagic colitis and HUS. Verotoxin enterococcal (VTEC)-associated HUS was seen in up to 20% of patients in recent outbreaks, mainly affecting children and the elderly (Dundas et al, 2001).
|1.||Epidemic form (D+) mostly with prodromal illness of bloody diarrhoea (90% VTEC identified)|
|2.||Sporadic form (D–) 2–7% VTEC identified|
|Non VTEC infections|
|Human immunodeficiency virus (Ray et al, 1999)|
|Streptococcus pneumoniae (Cabrera et al, 1998)|
|Aeromonas hydrophilia (Fang et al, 1999)|
|Campylobacter upsaliensis (Bourke et al, 1998)|
|Capnocytophaga canimorsus (Tobe et al, 1999)|
|Cytomegalovirus (Waiser et al, 1999)|
|1.||Post solid organ/bone marrow transplantation|
|Pentostatin (Antunes et al, 1999)|
|Cyclosporine (Kohli et al, 1998)/Tacrolimus (Schmidt et al, 1999)|
|Mitomycin C (Schiebe et al, 1998)/Estramustine (Tassinari et al, 1999)/Gemcitabine (Fung et al, 1999)|
|Interferon-β (Ubara et al, 1998)/Interferon-α in CML|
|Heroin (Peces et al, 1998)|
|Quinine (Hagley et al, 1992)|
|3.||Systemic lupus erythematosus (SLE)|
|6.||Familial deficiency or defect in complement factor H|
VT-producing organisms are characterized by their ability to produce one or more verocytoxins (or Shiga toxin S1 or S2) (Tesh & O'Brien, 1991) and it is these toxins that are implicated in the pathogenesis of HUS. After ingestion of contaminated food or water, the organisms bind to gut wall receptors and remain within the gut lumen (Nataro & Kaper, 1998). Toxin transfer has been proposed to target organs with specific globotriosyl ceramide (Gb) receptors, in particular glomerular microvascular endothelial cells (Zoja et al, 1992), via neutrophils (Te Loo et al, 2000). Binding occurs through the B subunits (Lingwood et al, 1987) of the toxin with subsequent internalization of the A subunit. The free A chain cleaves adenine from ribosomal RNA at a point where aminocyl transfer RNA is assembled causing disruption of peptide assembly and inhibition of protein synthesis (Obrig et al, 1987). In vitro VT binding can also induce apoptosis of some endothelial cell lines and primary cultures via a caspase-dependent mechanism (Lucas et al, 2000).
Laboratory features and investigations
Poor prognostic features at presentation include a high neutrophil count (Walters et al, 1989). Severe thrombocytopenia is uncommon but prolonged thrombocytopenia for more than 10 d is associated with long-term renal sequelae. Persistent proteinuria after 1 year may be associated with increased risk of progressive renal dysfunction (Moghal et al, 1998). Extended follow-up is therefore required in all patients. Haemolysis and red cell fragmentation are usually present at presentation, although this rarely develops later in the disease even after improvement in the platelet count. Coagulation studies are usually normal with only mildly raised D-dimer levels in contrast to disseminated intravascular coagulation (Rose & Chant, 1998). The VWF levels are usually markedly raised during the acute illness while multimeric analysis may or may not show ultra-large multimers (Rose et al, 1984). Factor VIII levels do not correlate with clinical outcome (Milford et al, 1991), but high PAI-1 levels correlate with time for platelet recovery and are associated with poor disease outcome (Chant et al, 1994). In contrast to TTP, a deficiency of VWF-CP was not identified in 28 out of 29 children with D+ HUS (25 VTEC positive) (Hunt et al, 2001). Early stool culture is essential for diagnosis of VTEC-associated HUS (Karch et al, 1995). Serological diagnosis is unhelpful in the acute phase, for while IgG enzyme-linked immunosorbent assays are reported to be 95% sensitive and 94% specific, current IgM assays are unreliable (Reymond et al, 1996).
Management of D+HUS
There are few randomized studies evaluating the therapeutic options in HUS. The prognosis for patients with D+ HUS has improved as a result of careful supportive management (Kaplan et al, 1998). Advice from a renal specialist should, therefore, be sought at the onset of any episode. Careful rehydration while avoiding over hydration, which may precipitate pulmonary oedema, is essential, as is careful management of hyponatraemia. Hypertension may be successfully treated with angiotensin-converting enzyme (ACE) inhibitors (Hoorntje et al, 1981; Monnens et al, 1981). Extra renal problems are now the main cause of mortality as control of blood pressure and appropriate use of dialysis have reduced the renal mortality and morbidity (Robson et al, 1991a). Bilateral nephrectomy may still be advocated in severe HUS unresponsive to any other treatment (Remuzzi et al, 1996; Ruggenenti & Remuzzi, 1996). Blood transfusions should be given according to clinical evaluation and platelet transfusions avoided as in the management of TTP. Extended follow-up is required as there is evidence for the development of both hypertension and renal impairment in the long term.
Based on retrospective data from two large outbreaks of E. coli 0157:H7, anti-motility agents are contraindicated in E. coli 0157:H7 infection (Cimolai et al, 1994). Treatment with anti-motility agents for more than 24 h are associated with the development of HUS and increased central nervous system problems (Cimolai et al, 1992). In the recent Scottish outbreak in Lanarkshire, adults with low gastric acid (previous gastrectomy or taking proton pump inhibitors) were at significantly increased risk of HUS and death. A recent prospective cohort study has confirmed the risk of HUS after antibiotic treatment is increased in children and antibiotics should, therefore, be avoided (Wong et al, 2000). Several antimicrobial agents increase the release of toxin from E. coli 0157:H7 in vitro (Grif et al, 1998), furthermore some are potent inducers of the Shiga toxin 2 gene (Zimmerhacki, 2000).
Recommendation. Optimal management of D+HUS requires meticulous fluid and electrolyte balance and blood pressure control (Grade C, level IV). Renal dialysis should be administered as required (Grade C, level IV). Anti-motility drugs and antibiotic treatment adversely affect outcome and should be avoided (Grade B, level III).
Fresh-frozen plasma and therapeutic plasma exchange. In two prospective studies of FFP in D+ HUS, no benefit in terms of the clinical course or outcome was identified (Loirat et al, 1988; Rizzoni et al, 1988). Potential risks of FFP include fluid overload, particularly in the young and elderly, hyperproteinaemia, hypertension, viral transmission and renal injury. Therefore, FFP has no proven benefit and is potentially harmful. There is no controlled prospective study in the use of therapeutic plasma exchange for D+ HUS. The outcomes of children treated with plasmapheresis have been reported but there is no evidence to support its current use (Gianviti et al, 1993). D+ HUS in adults usually occurs in elderly patients associated with increased neurological complications and a high mortality. Eleven out of 12 patients with D+ HUS in a Canadian Nursing Home outbreak not treated with plasma exchange died (Carter et al, 1987). Plasma exchange was used in 16 out of 22 patients in the Lanarkshire E. coli 0157:H7 outbreak with an overall mortality of 45% (Dundas et al, 1999). No conclusion as to the benefit of plasma exchange can be drawn from this report, in which 62% of the plasma exchange patients developed non-fatal pulmonary oedema.
Recommendation. At present there is no conclusive evidence that either FFP (Grade B, level IIa) or therapeutic plasma exchange improves outcome (Grade C, level IV).
Adjunctive treatment. Currently there is no evidence to support the use of anti-platelet agents (O'Regan et al, 1980), anticoagulation (Proesmans & Eeckels, 1974) or fibrinolytic agents (Loirat et al, 1984). While intravenous immunoglobulin has been shown to neutralize VT1 but not VT2 toxin, this has not been shown to be of benefit in D+ HUS (Robson et al, 1991b). Antioxidants, in particular vitamin E, have not been shown to improve patient outcomes. Methylprednisolone is not recommended as a randomized double blind trial failed to show any benefit in terms of blood transfusion requirements, reduction in seizures or need for renal dialysis (Perez et al, 1998).
Recommendation. Adjunctive treatment is not recommended in the management of HUS (Grade C, level IV).
Future developments. For children who develop HUS after VTEC colitis, the time between onset of diarrhoea and renal injury usually varies from 5 to 9 d. Synsorb-Pk, a synthetic trisaccharide covalently coupled to a chromosorb which binds both VT1 and VT2, is able to absorb VT in polymixin extracts of VT-producing E. coli and also to neutralize VT when mixed in vitro with VT-positive stools from children with haemorrhagic colitis or HUS following gastrointestinal transit (Armstrong et al, 1995). Randomized prospective trials of its administration in the prodromal period of VTEC infection are ongoing. Further strategies currently under evaluation include immunization with a modified Shiga toxin (Bast et al, 1997) and galexate mesilate, a serine protease reported to inhibit cytokine production by monocytes (Kusunoki et al, 1998).
In conclusion the management of D+ HUS is based on meticulous attention to fluid and electrolyte balance combined with renal dialysis where necessary. The benefit of additional treatments has not been proven and the principle of management is first to do no harm. Agents to modify the cytokine response seen in HUS or to inhibit platelet function of endothelial cell apoptosis should only be considered in the context of a randomized prospective trial.
Management of D–HUS
The optimal management of sporadic HUS is even less clear. This group represents a heterogeneous collection of patients with a substantially higher mortality and chronic morbidity than D+ HUS. Several familial cases have been linked with a deficiency or defect of complement factor H (Noris et al, 1998). Factor H controls the activity of the alternative complement pathway C3/C5 convertase by competing with Factor B for C3b binding. Reduced or abnormal factor H may fail to prevent excessive C3 activation, membrane deposition and endothelial cell injury. Reduced levels of C3 have been reported in 73% of patients with familial HUS compared with 16% of control subjects (P = 0·001) and is, therefore, recommended as a screening test for these patients (Noris et al, 1998). Historically patients have been treated with therapeutic plasma exchange, however, relapse rates remain high and it is of unproven benefit in prevention of progression to chronic renal failure (Ohali et al, 1998; Rougier et al, 1998; Warwicker et al, 1998, 1999). The replacement of factor H using plasma is a logical but unproven approach. It is recommended that these patients should be treated at a tertiary renal unit, with experience in managing such patients.
Diagnosis and therapy of thrombotic microangiopathy in pregnancy
The differential diagnosis of pregnancy-associated thrombotic microangiopathy (TMA) is presented in Table V and discussed below. Accurate diagnosis of TTP and HUS in pregnancy is complicated by the ability of pre-eclampsia to produce TMAs with a variety of clinical pictures similar to TTP and HUS. Each feature of the clinical pentad of TTP can occur in a woman with pre-eclampsia. Pre-eclampsia can also produce a unique TMA involving the liver: HELLP syndrome (haemolysis, elevated liver function tests, low platelets). Fever occurs rarely in HELLP and may be a useful distinguishing feature. Reviewing the literature, there are many patients described as TTP that are probably due to pre-eclampsia/HELLP, having resolved quickly post delivery on ineffective treatment and, vice versa, revision of a diagnosis of pre-eclampsia has to be made when a TMA fails to resolve post partum.
|Thrombotic thrombocytopenic purpura|
|Haemolytic uraemic syndrome|
|Acute fatty liver of pregnancy|
|Systemic lupus erythematosus/antiphospholipid syndrome|
|Disseminated intravascular coagulation|
Despite recent advances, there are no pathognomonic assays. The differentiation of these varying types of TMA in pregnancy remains based on history, physical examination and routine laboratory studies. As the management of TMA in pregnancy involves different approaches depending on the underlying diagnosis, the obstetrician and haematologist must distinguish the varying syndromes, to minimize maternal and fetal mortality (Weiner, 1987), and ensure the prompt delivery of efficacious, appropriate and cost-effective management. It is hoped that with the emergence of the understanding that TTP is related to a deficiency of VWF-cleaving protease, the clinical use of VWF-CP assays will bring clarity in diagnosis and management of TMA in pregnancy. This may, however, be obfuscated by the knowledge that levels of VWF-CP are reduced in the third trimester (Mannucci et al, 2001).
Differential diagnosis of TMAs in pregnancy
A summary of the differentiating presenting features and management of TMA in pregnancy is presented in Table VI.
|Diagnosis||Classic TTP||Post-partum HUS||HELLP||Pre-eclampsia/eclampsia|
|Time of onset||Usually < 24 weeks||Post partum||Usually > 34 weeks||Usually > 34 weeks gestation|
|Histopathology of lesions||Widespread platelet thrombi||Thrombi in renal glomeruli only||Hepatocyte necrosis & fibrin deposition in periportal sinusoids||Glomerular endothelial hypertrophy and occlusion of placental vessels|
|Effect on fetus||Placental infarct can lead to IUGR and mortality||None, if maternal disease is controlled||Associated with placental ischaemia and increased neonatal mortality||IUGR, occasional mortality|
|Effect of delivery on disease||None||None||Recovery, but may worsen transiently||Recovery, but may worsen transiently|
|Management||Early plasma exchange is imperative||Supportive ± plasma exchange||Supportive, consider plasma exchange if persists||Supportive ± plasma exchange|
Pre-eclampsia affects up to 4% of pregnancies; it most commonly occurs in nulliparous women or multiparous women with new partners. The criteria for diagnosis are new onset hypertension and proteinuria developing in the second half of pregnancy. Both hypertension and proteinuria characteristically regress after delivery. Most women also present with peripheral oedema. Pre-eclampsia is thought to involve and arise from a maternal systemic inflammatory response (Redman et al, 1999). Maternal endothelial activation is one part of this inflammatory response and, although it occurs in all pregnancies, it is pronounced in pre-eclampsia. A variety of putative circulating pre-eclampsia factors of placental origin have been proposed. These include lipid peroxidation (Hubel, 1999), vascular endothelial growth factor (VEGF) (Hayman et al, 1999), neurokinin B (Page et al, 2000), activin A (Muttukrishna et al, 1997) or apoptotic debris from the syncytial surface (Redman & Sargent, 2000). One manifestation of endothelial cell activation (ECA) is that the endothelial surface can change from an antithrombotic to prothrombotic phenotype (Hunt & Jurd, 1998). Evidence for this occurring in pre-eclampsia is supported by increased levels of PAI-1. Other prothrombotic changes include reductions in protein C and anti-thrombin. Coagulation activation is demonstrated by increased thrombin–anti-thrombin complexes (TAT) and D-dimers. Platelet activation also occurs and thrombocytopenia is common. However, profound DIC is a rare complication in the absence of placental abruption. The fall in anti-thrombin levels seen in pre-eclampsia is not found in TTP (Sagripanti et al, 1996) and may, therefore, be of diagnostic value.
HELLP is diagnosed in the presence of haemolysis, elevated liver enzymes and thrombocytopenia. At present there is no standardized definition for any of these criteria. HELLP occurs in up to 10% of women with severe pre-eclampsia. Severe thrombocytopenia and abnormal liver function can also present in the absence of significant hypertension or proteinuria. Exacerbations may occur post partum (Martin et al, 1990) and there is a risk of recurrence of approximately 3% in subsequent pregnancies (Sibai et al, 1995). Occasionally HELLP can present post partum, usually within 48 h of delivery, although it has been reported to occur as late as 6 days post partum (Schwartz & Brenner, 1985). Common presenting symptoms include nausea, malaise, epigastric or right upper quadrant abdominal pain and oedema (Sibai & Ramadan, 1993). In one large series, HELLP was frequently complicated by DIC (21%), abruption (16%), acute renal failure (8%) and pulmonary oedema (6%) (Sibai et al, 1993). Although mild increases in transaminases are present, profound renal failure or hepatic failure is uncommon in the absence of abruption and DIC, findings that help to distinguish HELLP from HUS and acute fatty liver of pregnancy respectively.
Although in some series, 10–25% of TTP episodes have been reported to be precipitated by pregnancy (Rose & Eldor, 1987), TTP in pregnancy is rare. As discussed previously, some of the former patients are likely to have been misdiagnosed. Debate continues as to whether TTP is precipitated by pregnancy, or whether the coincidence of pregnancy and TTP reflects the fact it is most common in women in their third and fourth decade. The prevalence of relapse during subsequent pregnancy suggests that pregnancy may be a precipitating factor (Rose & Eldor, 1987). Weiner (1987) reported that more than half the patients presenting in pregnancy occur at or before 24 weeks gestation. The diagnosis becomes difficult when TTP presents in the third trimester or post partum but the distinction of TTP from all other causes of TMA in pregnancy is vital because the disease is usually fatal in the absence of treatment and delivery has no effect on maternal outcome.
In 1968, a post-partum HUS was described (Robson et al, 1968; Wagoner et al, 1968), distinct from antepartum renal failure or renal failure occurring within 48 h post partum associated with poor renal perfusion due to obstetric emergencies. It typically presents subacutely with oliguric renal failure and TMA after an otherwise uncomplicated gestation and delivery. Primiparous women are most commonly affected. In one series, the mean time of onset was 26 d after delivery with all cases occurring within the first 10 weeks (Weiner, 1987). Rarely, patients have been described during gestation as a result of VT-producing Escherichia coli (Martinez-Roman et al, 1996). The presentation is that of acute renal failure with a microangiopathic haemolytic anaemia. It has also been associated with HELLP syndrome more than ‘pure’ pre-eclampsia or chronic hypertension (Kahra et al, 1998).
Anti-phospholipid syndrome (APS) and systemic lupus erythematosus (SLE)
Many patients with TMA in pregnancy described in the literature are associated with SLE and APS (Kincaid-Smith et al, 1988; Huang et al, 1998). A renal flare of SLE may mimic HUS and/or pre-eclampsia. Correct diagnosis of such patients may be aided by a history of arthralgia or cutaneous manifestations. The propensity for anti-phospholipid antibodies to predispose to pre-eclampsia is now recognized in the new International Classification Criteria for Anti-phospholipid Syndrome (Wilson et al, 1999): severe pre-eclampsia in association with anti-phospholipid antibodies is a new defining criterion. Furthermore, anti-phospholipid antibodies have also been reported to be associated with the development of TTP and HUS in pregnancy (Kniaz et al, 1992).
Acute fatty liver of pregnancy
This is a rare but potentially fatal cause of liver failure in the third trimester. The clinical picture is dominated by liver failure. Thrombocytopenia is usually mild. Haemolysis is not usually a feature, although pre-eclampsia may be present in half of the patients (Riely, 1987).
DIC in pregnancy
Recommendation. A thorough history and examination are required to differentiate the varying TMAs that can present in pregnancy. Routine investigations at presentation should include the following: full blood count, film, clotting screen, LDH, direct anti-globulin test, plasma haptoglobin, urea and electrolytes, liver function tests, and urine dipstick for protein. Anti-nuclear antibody, lupus anticoagulant and anti-cardiolipin antibody assays should be considered, depending on the history. Normal levels of anti-thrombin activity are helpful in discriminating TTP from pre-eclampsia (Grade C, level IV).
Despite extensive research into the causes and pathogenesis of this condition, delivery of the fetus and placenta is still the only effective treatment. The timing of delivery has been the subject of debate. There is a consensus that the presence of multiorgan dysfunction, fetal distress or a gestational age greater than 34 weeks warrants immediate delivery. However, delivery at earlier gestations is associated with high perinatal mortality and morbidity resulting from prematurity (Sibai et al, 1984; Chua & Redman, 1992). It may be possible to delay delivery when severe pre-eclampsia develops remote from term in an attempt to deliver a more mature neonate. A number of randomized controlled clinical trials have demonstrated that perinatal outcome may be improved without significantly compromising maternal outcome when this approach is adopted (Odendaal et al, 1990; Sibai et al, 1994). Meticulous clinical monitoring is required and any sign of maternal or fetal deterioration necessitates urgent delivery. If eclampsia develops, magnesium sulphate is the treatment of choice for seizure prophylaxis (The Eclampsia Trial Collaborative Group, 1995).
The neonatal mortality associated with HELLP is 10–20% and has been attributed to placental ischaemia leading to abruption, extreme prematurity and intrauterine asphyxia. Owing to modern management, the maternal death rate is less than 1%. Most authorities agree that expedited delivery is indicated for neonatal distress, abruption, maternal DIC or signs of progressive organ damage.
Corticosteroids given before or after delivery have been claimed to accelerate recovery of platelet count and haemolysis (Magann et al, 1994a,b; Martin et al, 1997), but no clear clinical benefit to mother or fetus has been found (Bell et al, 1991; Ruggeneti & Remuzzi, 1998). Retrospective observational studies suggest that FFP plasma exchange may help recovery in patients with persistent disease 72 h or more after delivery if there is persisting severe thrombocytopenia or haemolysis, or when there has been progressive hepatic, renal, pulmonary or CNS damage (Martin et al, 1990). However, plasma therapy is ineffective during pregnancy and may increase fetal and maternal risk when used to delay delivery (Weiner, 1987; Martin et al, 1990, 1994a, b). Haemostatic replacement therapy with FFP and platelets may be required for mothers with overt coagulopathy and bleeding.
Guidelines for the management of HELLP syndrome and pre-eclampsia-related TMA.Delivery is the treatment of choice and is usually followed by complete recovery within 24–48 h (Grade C, level IV). Persistent disease post partum may be an indication for plasmapheresis (Grade C, level IV).
Typically, maternal outcome is similar to that of the non-pregnant population assuming treatment is given (Hayward et al, 1994). Untreated TTP is not only associated with a poor outcome for the mother, but also the fetus as a result of the development of placental infarcts, leading to intrauterine growth restriction and death (Wurzel, 1979). However, successful treatment can result in the delivery of a normal-sized infant. Because TTP often develops before 24 weeks, when the fetus is unlikely to survive if delivered, and termination of pregnancy does not alter the clinical course of the disease, delivery or termination is not advocated. Fortunately pregnancy does not impair the response to plasmapheresis. No case of fetal thrombocytopenia has been described in maternal TTP. Pregnancy may precipitate relapse in women with a history of TTP (Hayward et al, 1994). There is anecdotal evidence to suggest the use of anti-platelet agents or steroids may prevent relapse (Ezra et al, 1996). Successful pregnancies have even occurred in women requiring maintenance plasma infusions preconception for the prevention of relapse. Increased plasma requirement may be noted during gestation (Lian et al, 1984; Koyama et al, 1990).
Guidelines for the management of TTP in pregnancy. Treat with plasma exchange as non-pregnant patients (Grade C, level IV). Delivery is recommended only for those women who do not respond to plasma exchange (Grade C, level IV).
Post-partum HUS has a poor prognosis. Chronic renal failure is common and a 55% mortality rate was found in earlier reports. Likewise Sibai et al (1993) reported a high maternal mortality rate of 13% and perinatal mortality rate of 34% in 32 patients with HELLP syndrome associated with renal failure (Sibai & Ramadan, 1993). Responses to plasmapheresis or plasma infusion have been reported but no form of management has been subjected to controlled studies (Weiner, 1987; Hayward et al, 1994; Martinez-Roman et al, 1996). The role of anti-platelet drugs, corticosteroids, heparin or splenectomy is even less well documented. Recurrence is rare, but the risk in women with familial HUS is uncertain (Berns et al, 1992).
Guidelines for the management of post-partum HUS. Supportive care with dialysis and transfusion is required (Grade C, level IV). The benefits of plasma exchange are uncertain (Grade C, level IV).
Routine audit of the clinical diagnosis and management of acute TTP and related conditions is difficult to conduct because of their infrequent presentation in most units. Larger haematological departments offering daily plasma exchange facilities should consider an annual review of disease outcome, time to diagnosis and initiation of specific therapy, time taken to clinical response, relapse rate, and long-term morbidity and mortality. Smaller departments should consider regional referral patterns, particularly delay in obtaining initiation of regular plasma exchange, and consider conducting an audit on a regional basis with long-term outcome and relapse rates (including mortality) after a course of plasma exchange has been completed. Such an approach should highlight any deficiency in service provision.
Despite recent advances, further clarification of the pathophysiology of the microangiopathic haemolytic anaemias is required to aid correct diagnosis, management and identification of those patients at risk of progressive disease or recurrent episodes. Objective clinical data is lacking and prospective controlled clinical trials of treatment are urgently required to improve clinical outcome in these conditions.
While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors nor the publishers can accept any legal responsibility or liability for any errors or omissions that may have been made.
The authors and Task Force wish to acknowledge the helpful constructive comments made on this document by society members. The authors are also grateful to the TTP Network and the following colleagues who gave valuable advice during the preparation of this manuscript: Dr T. Baglin (Cambridge), Professor T. Goodship (Newcastle), Professor M. Greaves (Aberdeen), Professor C. W. Redman (Oxford), Dr R. Trompeter (London) and Dr I. Walker (Glasgow).
- AABB Extracorporeal Therapy Committee (1992) Guidelines for Therapeutic Hemapheresis: 1992–1993. American Association of Blood Banks, Bethesda.
- 1997) Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. Journal of Cell Biology, 138, 1117–1124. , , , , & (
- 2000) von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 111, 1215–1222. , , , , & (
- 1998) Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation. American Journal of Hematology, 59, 9–14 . , , , , , , , , , , , & (
- 1999) Haemolytic uraemic syndrome induced by Pentostatin in a patient with cutaneous T cell lymphoma. Dermatology, 198, 179–180. , , , , , & (
- 1995) A phase I study of chemically synthesized verotoxin (shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic–uremic syndrome. Journal of Infectious Diseases, 171, 1042–1045. , , , , , , , , , , , & (
- 1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thrombosis Research, 38, 469–479. , , , & (
- 2000) Ten years of prophylactic treatment with fresh frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura due to a congenital deficiency of vWF-cleaving protease. Haemostasis, 30, 193a. , , , , , , & (
- 1997) Toxicity and immunogenicity of a Verotoxin 1 mutant with reduced globotriasyl ceramide receptor binding in rabbits. Infection and Immunity, 65, 2019–2028. , , & (
- 1991) Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Clinical experience in 108 patients. New England Journal of Medicine, 325, 398–403. , , & (
- 1998) Thrombotic thrombocytopenic purpura is associated with ticlopidine. Annals of Internal Medicine, 128, 541–544. , , , , & (
- 2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. New England Journal of Medicine, 342, 1773–1777. , , , , , , , , , , , & (
- 1992) Inherited hemolytic uremic syndrome in adults. American Journal of Kidney Diseases, 29, 331–334. , , & (
- 1990) Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet, 336, 565–566. , & (
- the Italian Cooperative Group for TTP (1994) Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. European Journal of Haematology, 52, 222–226. , , , , , , , &
- for the Italian Co-operative Group for TTP (1997) Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomised multicenter trial by the Italian Cooperative Group for TTP. Haematologica, 82, 429–435. , , , , , , &
- 1998) Campylobacter upsaliensis: waiting in the wings. Clinical Microbiology Reviews, 11, 440–449. , & (
- 1998) Haemolytic uraemic syndrome associated with invasive streptococcus pneumoniae infection. Pediatrics, 101, 699–703. , , , , & (
- 1987) A severe outbreak of Eschericia coli 0157:H7 associated haemorrhagic colitis in a nursing home. New England Journal of Medicine, 24, 1496–1500. , , , , , , , & (
- 1994) Plasminogen activator inhibitor activity in diarrhoea associated haemolytic uraemic syndrome. Quarterly Journal of Medicine, 87, 737–740. , & (
- 1992) Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. Journal of Paediatrics, 120, 49–53. , , , & (
- 1992) Prognosis for pre-eclampsia complicated by 5g or more of proteinuria in 24 hours. European Journal of Obstetrics, Gynecology and Reproductive Biology, 43, 9–12. & (
- 1992) Risk factors for the central nervous system manifestations of gastroenteritis associated haemolytic uraemic syndrome. Paediatrics, 90, 616–621. , & (
- 1994) A continuing assessment of risk factors for the development of Eschericia coli 0157:H7 associated haemolytic uraemic syndrome. Clinical Nephrology, 42, 85–89. , , , & (
- 1996) Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Annals of Internal Medicine, 125, 294–296. , , , & (
- 1991) Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. Journal of Clinical Investigation, 88, 774–782. , & (
- 1993) Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Eschericia coli sepsis. American Journal of Pathology, 142, 1458–1470. , , & (
- 1999) The clinical management of E. coli 0157 infection. CPD Infection, 1, 14–19. & (
- 1999) Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Eschericia coli 0157:H7 outbreak. Lancet, 354, 1327–1330. , , , , & (
- 2001) The central Scotland 1996 Eschericia coli 0157 outbreak: predicotors of haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura and death. Clinical Infectious Diseases, 33, 923–931. , , , , & (
- 1999) Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clinical and Laboratory Haematology, 21, 119–123. , , , & (
- 1996) Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies. American Journal of Hematology, 51, 1–6. , & (
- 1999) Haemolytic uraemic syndrome in an adult male with Aeromonas hydrophilia enterocolitis. Nephrology, Dialysis and Transplantation, 14, 439–440. , , & (
- 2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 98, 1662–1666. , , & (
- 1999) A review of haemolytic uraemic syndrome in patients with gemcitabine therapy. Cancer, 85, 2023–2032. , , , , & (
- 1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 87, 4223–4234. , & (
- 1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 89, 3097–3103. , , , , & (
- 1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. New England Journal of Medicine, 339, 1578–1584. , , , , , , , , , , & (
- 1997) Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. American Journal of Hematology, 55, 55–58. , , , , & (
- 1955) Hämolytisch–urämische syndrome: bilaterale nierendrinndennekrosen bei akuten erworbenen hämolytischen anämien. Scweizerische Medizinische Wochenschrift, 85, 905–909. , , , & (
- 2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood, 98, 1654–1661. , , & (
- 1993) Plasma exchange in children with hemolytic–uremic syndrome at risk of poor outcome. American Journal of Kidney Diseases, 22, 264–266. , , , , , & (
- 1987) Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Seminars in Hematology, 24, 194–201. , & (
- 1998) Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Eschericia coli following exposure to sub inhibitory concentrations of antimicrobial agents. European Journal of Clinical Microbiology and Infectious Diseases, 17, 761–766. , , & (
- 1992) Haemolytic uraemic syndrome associated with ingestion of quinine. American Journal of Nephrology, 12, 192–195. , , & (
- 1998) Successful use of cyclosporin A in the treatment of refractory thrombotic thrombocytopenic purpura. British Journal of Haematology, 100, 597–599. , , & (
- 1981) Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. Journal of the American Medical Association, 246, 1931–1933. , , , & (
- 1996) Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. British Journal of Haematology, 94, 756–758. , , , & (
- 1999) Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. Journal of the Society for Gynecological Investigation, 6, 3–10. , , & (
- 1994) Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura–haemolytic syndrome. Archives of Internal Medicine, 154, 982–987. , , & (
- 1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine, 340, 409–417. & (
- 1981) Reversal of long-standing renal insufficiency by captopril in a patient with relapsing hemolytic uremic syndrome due to an oral contraceptive. Annal of Internal Medicine, 94, 355–357. & (
- 1998) Post partum haemolytic uraemic syndrome associated with antiphospholipid antibody. Nephrology, Dialysis and Transplantation, 13, 182–186. & (
- 1999) Oxidative stress in the pathogenesis of preeclampsia. Proceedings of the Society for Experimental Biology and Medicine, 222, 222–235. (
- 2001) von Willebrand factor cleaving protease in childhood diarrhoea associated haemolytic uraemic syndrome. Thrombosis and Haemostasis, 85, 975–978. & (
- 1998) Endothelial cell activation. British Medical Journal, 316, 1328–1329. & (
- 1998) Post partum renal failure: a complex case with probable coexistence of hemolysis, elevated liver enzymes, low platelet count, and haemolytic uremic syndrome. Obstetrics and Gynaecology, 92, 698–700. & (
- 1998) The pathogenesis and treatment of hemolytic uremic syndrome. Journal of the American Society of Nephrology, 9, 1126–1133. & (
- 1995) Isolation of enterohaemorrhagic Eschericia coli 0157 strain from patients with haemolytic uramic syndrome by using immunomagnetic separation, DNA based methods and direct culture. Journal of Clinical Microbiology, 34, 516–519. & (
- 1996) Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. Kidney International, 49, 190–199. & (
- 1997) von Willebrand factor mediates increased platelet retention in recurrent thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 78, 1456–1462. & (
- 1999) Renal involvement of thrombotic thrombocytopenic purpura: special reference to the glomeruloid structures. Pathology International, 49, 638–642. & (
- 1988) Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Quarterly Journal of Medicine, 258, 795–851. & (
- 1992) Post partum hemolytic–uraemic syndrome associated with antiphospholipid antibodies. American Journal of Nephrology, 12, 126–133. & (
- 1998) Cyclosporin induced haemolytic uraemic syndrome presenting as primary graft dysfunction. Nephrology, Dialysis and Transplantation, 13, 2940–2942. & (
- 1990) Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli 0157:H7. American Journal of Medicine, 88, 177–179. & (
- 1990) Efficiency of the high molecular weight fraction of plasma for the maintenance of pregnancy associated with thrombotic thrombocytopenic purpura. American Journal of Hematology, 35, 179–183. & (
- 1998) Gabexate mesilate plus intravenous gammaglobulin treatment in children with diarrhoea–associated haemolytic uraemic syndrome. Nephron, 79, 227–228. & (
- 2001) Severe constitutional deficiency of von Willebrand factor-cleaving protease (vWF-cp) in 23 patients with familial thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, a. & (
- 2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488–494. & (
- 1984) Two successful pregnancies in women with chronic thrombotic thrombocytopenic purpura treated by plasma infusion. American Journal of Hematology, 16, 287–291. & (
- 1987) Glycolipid binding of purified and recombinant E. coli produced verotoxin in vitro. Journal of Biological Chemistry, 262, 8834–8839. & (
- 1984) Traitement du syndrome hemolytique et uremique de l'enfant par l'urokinase, Essai controle cooperatif. Archives Francaises Pediatrie, 41, 15–19. & (
- 1988) Treatment of childhood haemolytic uraemic syndrome with plasma. A multicentre randomised controlled trial. Pediatric Nephrology, 2, 279–285. & (
- 2001) Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. British Journal of Haematology, 112, 1087–1088. & (
- 2000) Contrasting effects of HSP 72 expression on apoptosis in human umbilical vein endothelial cells and an angiogenic cell line EC304. British Journal of Haematology, 110, 957–964. & (
- 1997) Septic shock in pregnancy. Obstetrics and Gynaecology, 90, 553–561. & (
- 1994a) Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). American Journal of Obstetrics and Gynecology, 171, 1148–1153. (
- 1994b) Post partum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated lever enzymes, and low platelets (HELLP). American Journal of Obstetrics and Gynecology, 171, 1154–1158. , , , , & (
- 1997) HIV-related thrombotic thrombocytopenic purpura: report of two cases and a review of the literature. Netherlands Journal of Medicine, 51, 103–109 . , , & (
- 2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood, 98, 2730–2735. , , , , & (
- 1990) Plasma exchange for pre-eclampsia: post partum use for persistently severe pre-eclampsia–eclampsia with HELLP syndrome. American Journal of Obstetrics and Gynecology, 162, 126–137. , , , , , , & (
- 1994a) Plasma exchange for pre-eclampsia: immediate peripartum utilization for selected patients with HELLP syndrome. Journal of Clinical Apheresis, 9, 162–165. , , , , , & (
- 1994b) Plasma exchange for pre-eclampsia: unsuccessful antepartum utilization for severe pre-eclampsia with or without HELLP syndrome. Journal of Clinical Apheresis, 9, 155–161. , , , , , & (
- 1997) Better maternal outcomes are achieved with dexamethasone therapy for post partum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. American Journal of Obstetrics and Gynecology, 177, 1011–1017. , , , , & (
- 2000) Experience with methylene blue virus-inactivated plasma in the treatment of thrombotic thrombocytopenic purpura (TTP). Vox Sanguines, 78, P224a. , , , , , , & (
- 1996) Successful pregnancy in a patient with hemolytic–uremic syndrome during the second trimester of pregnancy. Journal of Reproductive Medicine, 41, 211–214. , , , , & (
- 1998) Treatment of thrombotic thrombocytopenic purpura: a role for early vincristine administration. Journal of Clinical Apheresis, 13, 20–22. , , & (
- 1990) Haemolytic uraemic syndrome in the British Isles 1985–88: association with verotoxin producing Eschericia coli. Part I: Clinical and epidemiological aspects. Archives of Disease in Childhood, 65, 716–721. , , , , & (
- 1991) Prognostic markers in diarrhoea associated haemolytic uraemic syndrome: initial neutrophil count, neutrophil elastase and von Willebrand antigen. Nephrology, Dialysis and Transplantation, 6, 232–237 . , , , , & (
- 1985) Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 65, 1232–1236. , , , , , & (
- 1989) Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenenic purpura and the haemolytic uraemic syndrome. American Journal of Medicine, 87, 3N–9N. & (
- 1994) Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood, 84, 490–497. , , , , , , , & (
- 1998) The late histologic findings in diarrhea associated hemolytic uremic syndrome. Journal of Pediatrics, 132, 220–223. , , , , & (
- 1994) Therapeutic plasma exchange: complications and management. American Journal of Kidney Diseases, 23, 817–827. & (
- 1993) Refractory thrombotic thrombocytopenic purpura: successful treatment by plasmapheresis with plasma cryosupernatant. Haematologica, 78, 389–392. , , , , & (
- 1981) Malignant hypertension in a child with hemolytic–uremic syndrome treated with captopril. Acta Paediatrica Scandinavica, 70, 583–585. , & (
- 1991) Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. Thrombosis and Haemostasis, 66, 515–519. , , , , , , & (
- 1986) Colonic biopsy in verotoxin-induced hemorrhagic colitis and thrombotic thrombocytopenic purpura (TTP). American Journal of Clinical Pathology, 86, 108–112. , & (
- 1924) Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proceedings of the New York Pathological Society, 24, 21–24. (
- 1997) Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet, 349, 1285–1288. , , , & (
- 1998) Diarrheagenic Eshericia coli. Clinical Microbiology Reviews, 11, 142–201. & (
- on behalf of the Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenia Purpura (1998) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Journal of the American Society of Nephrology, 10, 281–293. , , , , , , , &
- 1992) Vincristine therapy for thrombotic thrombocytopenic purpura. American Journal of Hematology, 39, 234–236. , & (
- 1980) Aspirin and dipyridamole therapy in the haemolytic uraemic syndrome. Journal of Paediatrics, 97, 473–476. , & (
- 1987) The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochemical Journal, 244, 287–294. , & (
- 1990) Aggressive or expectant management for patients with severe preeclampsia between 28 and 34 weeks' gestation: a randomised controlled trial. Obstetrics and Gynaecology, 76, 1070–1075. , , , & (
- 1998) Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatric Nephrology, 12, 619–624. , , , , , , & (
- 1999) Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Research, 59, 2244–2250. , & (
- 2000) Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature, 15, 797–800. , , , , , , & (
- 1998) Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. American Journal of Hematology, 57, 57–61. , , , , & (
- 1998) Haemolytic uraemic syndrome in a heroin addict. Nephrology, Dialysis and Transplantation, 13, 3197–3199. , , , & (
- 1995) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Annals of Hematology, 70, 319–323. , , , , , , & (
- 1998) Steroids in the hemolytic uremic syndrome. Pediatric Nephrology, 12, 101–104. , , , , & (
- 1996) Cryoprecipitate-poor plasma fraction (cryosupernatant) in the treatment of thrombotic thrombocytopenic purpura at onset. A report of four cases. Haematologica, 81, 175–177. , , & (
- 1999) von Willebrand factor proteolysis is deficient in classic, but not in bone marrow-associated thrombotic thrombocytopenic purpura. Blood, 93, 3798–3802. , , , , , & (
- 1974) Has heparin changed the prognosis of the hemolytic–uremic syndrome. Clinical Nephrology, 2, 169–173. & (
- 1999) Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome. Pediatric Nephrology, 13, 586–593. , , & (
- 2000) Placental debris, oxidative stress and pre-eclampsia. Placenta, 21, 597–602. & (
- 1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. American Journal of Obstetrics and Gynecology, 180, 499–506. , & (
- 1995) The hemolytic uremic syndrome. Kidney International, 48, 2–19. & (
- 1996) Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney International, 49, 282–286. , , , , & (
- 1996) Neutralising antibodies to Eschericia coli Vero Cytotoxin 1 and antibodies to 0157 lipopolysaccharide in healthy farm family members and urban residents. Journal of Clinical Microbiology, 34, 2053–2057. , , , , , , , , , & (
- 1987) Acute fatty liver of pregnancy. Seminars in Liver Disease, 7, 47–54 . (
- 1988) Plasma infusion for hemolytic uremic syndrome in children: results of a multicenter controlled trial. Journal of Pediatrics, 12, 284–290. , , , , , , , , & (
- 1968) Irreversible post-partum renal failure: a new syndrome. Quarterly Journal of Medicine, 37, 423–435. , , & (
- 1991a) Causes of death in hemolytic uremic syndrome. Child Nephrology and Urology, 11, 84–86. , & (
- 1991b) The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome. Pediatric Nephrology, 5, 289–292. , , & (
- members of the Canadian Aphereis Group (1998) Laboratory abnormalities in thrombotic thrombocytopenic purpura. British Journal of Haematology, 103, 1031–1036. , , , , , &
- the Canadian Apheresis Group (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New England Journal of Medicine, 325, 393–397. , , , , , , &
- members of the Canadian Apheresis Group (1996) Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. British Journal of Haematology, 94, 383–386. , , , , , &
- 1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. American Journal of Medicine, 83, 437–444. & (
- 1998) Hematology of hemolytic–uremic syndrome. In: Eschericia coli 0157:H7 and other Shiga Toxin-Producing E. coli Strains (ed. by J.B. & A.D. ), p. 293. American Society for Microbiology, Washington. & (
- 1984) Abnormalities of factor VIII related protein multimers in the haemolytic uraemic syndrome. Archives of Disease in Childhood, 59, 1135–1140. , , , , & (
- 1982) Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Annals of Internal Medicine, 96, 27–33. , & (
- 1998) Human complement factor H deficiency associated with hemolytic uremic syndrome. Journal of the American Society of Nephrology, 9, 2318–2326. , , , , , , , , , , & (
- 1996) Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. American Journal of Kidney Diseases, 27, 459–475. & (
- 1998) Pathophysiology and management of thrombotic microangiopathy. Journal of Nephrology, 11, 300–310. & (
- 1996) Plasmatic parameters of coagulation activation in thrombotic microangiopathy. Biomedicine and Pharmacotherapy, 50, 357–362. , , , , , & (
- 1997) Thrombotic thrombocytopenic purpura: early and late responders. American Journal of Hematology, 54, 102–107. , , & (
- 1998) Mitomycin C-related haemolytic uraemic syndrome in cancer patients. Anticancer Drugs, 9, 433–435. , , & (
- 1999) Haemolytic uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. Nephrology, Dialysis and Transplantation, 14, 979–983. , , , & (
- 1985) Severe preeclampsia with persistent post partum hemolysis and thrombocytopenia treated by plasmapheresis. American Journal of Obstetrics and Gynecology, 65, s53– s55. & (
- 1994) Spectrum of extrarenal involvement in post diarrheal haemolytic uraemic syndrome. Journal of Paediatrics, 125, 511–518. (
- the Canadian Apheresis Group (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Annals of Internal Medicine, 122, 569–572. , , &
- 1993) Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes and low platelets. American Journal of Obstetrics and Gynecology, 168, 1682–1690. & (
- 1984) Pregnancy outcome in 303 cases with severe preeclampsia. Obstetrics and Gynaecology, 64, 319–325. , , , & (
- 1993) Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). American Journal of Obstetrics and Gynecology, 169, 1000–1006. , , , , & (
- 1994) Aggressive versus expectant management of severe preeclampsia at 28–32 weeks' gestation: a randomzed controlled trial. American Journal of Obstetrics and Gynecology, 171, 818–822. , , & (
- 1995) Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. American Journal of Obstetrics and Gynecology, 172, 125–129. , , & (
- 1998) Treatment of relapsing thrombotic thrombocytopenic purpura with cyclophosphamide pulse therapy. Nephrology, Dialysis and Transplantation, 13, 1320–1321. , , , , , , & (
- 1999) Hemolytic uremic syndrome during therapy with estramustine phosphate for advanced prostatic cancer. Oncology, 56, 112–133. , , , & (
- 2000) Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood, 95, 3396–3402. , , , , , , & (
- 1991) The pathogenic mechanisms of Shiga toxin and the shiga-like toxins. Molecular Microbiology, 5, 1817–1822. & (
- The Eclampsia Trial Collaborative Group (1995) Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet, 345, 1455–1463.
- 1999) Hemolytic uremic syndrome due to Caprocytophaga canimorsus bacteraemia after a dog bite. American Journal of Kidney Diseases, 33, E5. , , , & (
- 1995) Increasing mortality from thrombotic thrombocytopenic purpura in the United States: analysis of national mortality data. American Journal of Hematology, 50, 84–90. , & (
- 1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 4235–4244. (
- 1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585–1594. & (
- 1991) Subunit composition of plasma von Willebrand factor multimers: evidence for a non-proteolytic mechanism resulting in apparent increase in proteolytic fragments. Thrombosis Research, 63, 179–188. , & (
- 2000) Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Annals of Internal Medicine, 132, 794–799. , , , & (
- 1998) Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis. Nephron, 80, 107–108. , , , , , , , , , , , , , & (
- 1994) Thrombotic microangiopathy and retroviral infections: a 13-year experience. American Journal of Hematology, 45, 304–309. , , , & (
- 1990) Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet, 336, 1508–1509. & (
- 1978) Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. New England Journal of Medicine, 298, 1350–1352. (
- 1997) Cyclosporine for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation. British Journal of Haematology, 96, 641–643. , , , & (
- 2000) Thrombotic thrombocytopenic purpura (TTP) versus hemolytic–uremic syndrome (HUS) in adults: analysis of clinical features and outcomes. Blood, 96, 630a. , , & (
- 2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood, 98, 1765–1772. , , , & (
- 1998) Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. American Journal of Hematology, 58, 189–194. , , , , , , , , , , & (
- 1968) Accelerated nephrosclerosis and post partum acute renal failure. Quarterly Journal of Medicine, 37, 423–435. , & (
- 1999) De novo hemolytic uremic syndorme post renal transplant after cytomegalovirus infection. American Journal of Kidney Diseases, 34, 556–559. , , , & (
- 1989) The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatric Nephrology, 3, 130–134. , , , & (
- 1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney International, 53, 836–844. , , , , , , & (
- 1999) Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrology, Dialysis and Transplantation, 14, 1229–1233. , , , , , , & (
- 1987) Thrombotic microangiopathy in pregnancy and the post partum period. Seminars in Hematology, 23, 119–129. (
- 1990) Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis. American Journal of Hematology, 35, 18–21. , & (
- 1999) Treating patients with severe sepsis. New England Journal of Medicine, 340, 207–214. & (
- 1986) Expression and intracellular distribution of stress fibres in aortic endothelium. Journal of Cell Biology, 103, 63–70. & (
- 1999) International consensus statement for the preliminary classification criteria for definite antiphospholipid syndrome. Arthritis and Rheumatism, 42, 1309–1311. , , , , , , , , , , & (
- 2000) The risk of the hemolytic uremic syndrome after antibiotic treatment of Eschericia coli 0157:H7 infections. New England Journal of Medicine, 342, 1930–1936. , , , & (
- 1979) TTP lesions in the placenta but not in the fetus. New England Journal of Medicine, 301, 503–504. (
- the North America TTP Group (2001) Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). Journal of Clinical Apheresis, 16, 19–22. , , , , , , , , &
- 2000) E. coli antibiotics and the haemolytic uraemic syndrome. New England Journal of Medicine, 342, 1990–1991. (
- 1986) Subunit composition of plasma von Willebrand factor: cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID and IIE). Journal of Clinical Investigation, 77, 947–951. , , & (
- 1992) Verotoxin glycoplipid receptors determine the localization of microangiopathic process in rabbits given verotoxin 1. Journal of Laboratory and Clinical Medicine, 120, 229–238. , , , , , , , & (